Related Experiment Video
Updated: Apr 16, 2026

Tick Microbiome Characterization by Next-Generation 16S rRNA Amplicon Sequencing
Published on: August 25, 2018
Report on the 56th ASH Annual Meeting, San Francisco, 4-9 December 2014
1Hematoncology Division, European Institute of Oncology, Milan, Italy.
Insights
The 56th American Society of Haematology meeting highlighted targeted therapies like anti-PD-1 and CAR-T cells for blood cancers. Intensive chemotherapy is also feasible for older patients with aggressive hematologic diseases.
Area of Science:
- Hematology
- Oncology
- Immunotherapy
Background:
- The 56th American Society of Haematology (ASH) meeting convened in San Francisco.
- Over 3,000 abstracts were presented, covering basic science to clinical hematology.
- Key themes included advancements in targeted therapies and treatment strategies for aggressive hematologic malignancies.
Purpose of the Study:
- To summarize key findings and future directions presented at the 56th ASH meeting.
- To highlight progress in targeted therapies for hematologic disorders.
- To discuss evolving treatment paradigms for aggressive hematologic diseases.
Main Methods:
- Review of abstracts and presentations from the 56th ASH meeting.
- Synthesis of information on targeted therapies (e.g., anti-PD-1, CAR-T cells, immunomodulatory agents).
- Analysis of clinical studies on intensive chemotherapy for older patients with AML and ALL.
Main Results:
- Targeted therapies are becoming central to treating lymphoproliferative disorders and multiple myeloma.
- Novel immunomodulatory agents show promise in the bone marrow microenvironment for multiple myeloma.
- Clinical studies confirmed the feasibility of intensive chemotherapy in older patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
Conclusions:
- The future of hematology/oncology is increasingly focused on precision medicine and immunotherapy.
- Treatment strategies are adapting to incorporate advanced therapies for various hematologic conditions.
- Intensive chemotherapy remains a viable option for select older patients with aggressive hematologic cancers.
Abstract:
The 56th annual ASH (American Society of Haematology) meeting was held in San Francisco (CA). More than 3,000 abstracts were selected for presentation due to the huge amount of information from basic science to clinical experience. The future direction in haematoncology is targeted therapies for most diseases; for instance, anti-PD-1 and CAR-T cells in lymphoproliferative disorders and novel immunomodulatory agents active in the contest of bone marrow milieu in multiple myeloma. On the other hand, in aggressive haematological diseases (AML, ALL), clinical studies demonstrated the feasibility of a more intensive chemotherapy approach in older patients.
Related Concept Videos
SBAR II: Application of SBAR
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
Chair Conformation of Cyclohexane
The hydrogen atoms linked to carbons are arranged in two different axial and equatorial orientations to achieve this...
Assembly of Signaling Complexes
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
Atomic Force Microscopy
The AFM Probe
The probe is regarded as the heart of any AFM setup and comprises the...
National Nursing Organizations II
The AACN emphasizes a healthy work environment through six standards to achieve an optimal patient outcome. The standards are appropriate staffing, meaningful recognition, collaboration, authentic leadership, effective communication, and decision-making. In addition, AACN provides certification programs, webinars, journals, and...
Assembly of Cytoskeletal Filaments

